Medical marijuana is already approved in over half of the U.S. Todd Hagopian says we will soon see a tipping point in which medical marijuana companies will be transformed from fringe enterprises trading at a discount into mainstream biotech companies with premium valuations. Until we reach that tipping point, however, the cannabis-based segment of the biotech sector is ripe for acquisitions.